Clinical Trial Update: A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Nivolumab plus Bempegaldesleukin versus Nivolumab alone and standard of care in cisplatin-ineligible muscle-invasive bladder cancer comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Bempeg (bempegaldesleukin)
• OPDIVO (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Bladder Cancer, Bladder Tumor | Phase 3 | Status: COMPLETED | Results posted: 2024-06-27